IN8bio (INAB) Competitors $2.31 +0.16 (+7.44%) Closing price 04:00 PM EasternExtended Trading$2.24 -0.07 (-3.03%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INAB vs. EQ, PMN, BDRX, LGVN, QTTB, NAII, RLYB, DARE, ELEV, and AYTUShould you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Equillium (EQ), Promis Neurosciences (PMN), Biodexa Pharmaceuticals (BDRX), Longeveron (LGVN), Q32 Bio (QTTB), Natural Alternatives International (NAII), Rallybio (RLYB), Dare Bioscience (DARE), Elevation Oncology (ELEV), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. IN8bio vs. Its Competitors Equillium Promis Neurosciences Biodexa Pharmaceuticals Longeveron Q32 Bio Natural Alternatives International Rallybio Dare Bioscience Elevation Oncology Aytu BioPharma Equillium (NASDAQ:EQ) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Which has more volatility & risk, EQ or INAB? Equillium has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Does the media refer more to EQ or INAB? In the previous week, Equillium had 1 more articles in the media than IN8bio. MarketBeat recorded 4 mentions for Equillium and 3 mentions for IN8bio. IN8bio's average media sentiment score of 1.00 beat Equillium's score of 0.28 indicating that IN8bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EQ or INAB more profitable? IN8bio has a net margin of 0.00% compared to Equillium's net margin of -19.62%. Equillium's return on equity of -74.34% beat IN8bio's return on equity.Company Net Margins Return on Equity Return on Assets Equillium-19.62% -74.34% -46.75% IN8bio N/A -218.85%-139.59% Do institutionals & insiders believe in EQ or INAB? 27.1% of Equillium shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 31.6% of Equillium shares are held by insiders. Comparatively, 15.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has stronger earnings and valuation, EQ or INAB? Equillium has higher revenue and earnings than IN8bio. Equillium is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$41.10M0.43-$8.07M-$0.39-1.27IN8bioN/AN/A-$30.44M-$13.57-0.17 Do analysts prefer EQ or INAB? Equillium currently has a consensus target price of $3.00, suggesting a potential upside of 505.82%. IN8bio has a consensus target price of $180.00, suggesting a potential upside of 7,692.21%. Given IN8bio's stronger consensus rating and higher probable upside, analysts plainly believe IN8bio is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33IN8bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEquillium beats IN8bio on 8 of the 14 factors compared between the two stocks. Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INAB vs. The Competition Export to ExcelMetricIN8bioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.99M$2.98B$5.45B$9.68BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-0.1717.9230.0525.00Price / SalesN/A174.46378.2478.85Price / CashN/A41.8335.9458.58Price / Book0.397.278.145.68Net Income-$30.44M-$54.43M$3.25B$265.58M7 Day Performance9.48%0.00%1.16%2.51%1 Month Performance5.00%5.14%2.82%1.88%1 Year Performance-88.74%10.25%28.41%24.02% IN8bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INABIN8bio3.9417 of 5 stars$2.31+7.4%$180.00+7,692.2%-89.9%$6.99MN/A-0.1720News CoveragePositive NewsEarnings ReportUpcoming EarningsEQEquillium2.8531 of 5 stars$0.56-20.7%$3.00+432.6%-24.7%$25.36M$41.10M-1.4440Upcoming EarningsPMNPromis Neurosciences2.0173 of 5 stars$0.70-8.5%$4.33+518.1%-60.4%$25.06MN/A-14.025News CoverageUpcoming EarningsBDRXBiodexa Pharmaceuticals0.1013 of 5 stars$6.98+4.2%N/AN/A$24.48M$470K0.0020Short Interest ↑Gap UpLGVNLongeveron3.0127 of 5 stars$1.71+4.6%$8.67+406.8%-50.6%$24.41M$2.39M-0.2720Upcoming EarningsShort Interest ↑Trading HaltedQTTBQ32 Bio2.0415 of 5 stars$1.93-3.5%$12.17+530.4%-95.5%$24.40M$1.16M-0.3939Earnings ReportShort Interest ↑Gap DownNAIINatural Alternatives InternationalN/A$3.71+2.8%N/A-30.5%$22.31M$113.80M-2.67290Positive NewsRLYBRallybio2.4435 of 5 stars$0.53-1.1%$10.00+1,790.4%-57.4%$22.26M$848K-0.4940Positive NewsDAREDare Bioscience1.3049 of 5 stars$2.39-1.2%$12.00+402.1%-36.8%$21.85M$10K-14.0630Upcoming EarningsELEVElevation Oncology2.1127 of 5 stars$0.37flat$3.39+827.6%N/A$21.62MN/A-0.4540AYTUAytu BioPharma3.1981 of 5 stars$2.65+10.4%$10.00+277.4%-3.8%$21.55M$81M-3.68160High Trading Volume Related Companies and Tools Related Companies EQ Competitors PMN Competitors BDRX Competitors LGVN Competitors QTTB Competitors NAII Competitors RLYB Competitors DARE Competitors ELEV Competitors AYTU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INAB) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IN8bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INAB Stock Alerts